IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.3929
-0.0062 (-1.55%)
At close: Oct 13, 2025, 4:00 PM EDT
0.3929
0.00 (0.00%)
After-hours: Oct 13, 2025, 6:33 PM EDT
IGC Pharma Employees
IGC Pharma had 70 employees as of March 31, 2025. The number of employees increased by 3 or 4.48% compared to the previous year.
Employees
70
Change (1Y)
3
Growth (1Y)
4.48%
Revenue / Employee
$18,957
Profits / Employee
-$90,600
Market Cap
36.13M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 70 | 3 | 4.48% |
| Mar 31, 2024 | 67 | 6 | 9.84% |
| Mar 31, 2023 | 61 | 9 | 17.31% |
| Mar 31, 2022 | 52 | 2 | 4.00% |
| Mar 31, 2021 | 50 | 0 | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IGC News
- 2 days ago - IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders - Accesswire
- 6 days ago - IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease - Accesswire
- 14 days ago - IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial - Accesswire
- 19 days ago - IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology - Accesswire
- 21 days ago - IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial - Accesswire
- 4 weeks ago - IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection - Accesswire
- 5 weeks ago - IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada - Accesswire
- 6 weeks ago - IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome - Accesswire